Therapeutic potential of the genus Bacteroides in hypertension: an intervention of long-term intermittent fasting

Intermittent fasting has shown promise in the management of hypertension, but the mechanistic explanation for this effect remains largely obscure. Studies in experimental animals suggest that intermittent fasting acts on hypertension by modifying the microbiome and particularly by increasing levels of intestinal Bacteroides. Human data, however, are lacking. Here we conducted a clinical trial [ChiCTR2000034646] to investigate the effects of 15-week intermittent fasting on individuals with hypertension. We observe that long-term intermittent fasting effectively counteracts high blood pressure, as demonstrated by significant reduction in systolic blood pressure (144±4.8 [S.E.M.] mmHg at baseline vs. 129±5.6 mmHg at 15 weeks, p=0.004) and diastolic blood pressure (94±5.2 mmHg vs. 79±2.9 mmHg, p=0.005), as well as serum uric acid (410 ± 38 mmol/L at baseline vs. 307 ± 5.5 mmol/L at 15 weeks, p=0.032), which is a strong risk marker for hypertension. Importantly, this effect is associated with significant remodeling of the fecal microbiome (p=0.041). Mirroring earlier data in experimental rodents, we observe a strong inverse correlation between levels of genus Bacteroides and blood pressure (R=-0.608, p=0.04). Our results strongly support the notion that the genus Bacteroides is a major determinant of blood pressure in hypertensive individuals.